TH33487B - Rabies vaccine that does not cause disease - Google Patents

Abstract

This invention relates to a non-pathogenic rabies vaccine consisting of a non-pathogenic mutant rabies virus strain SAD, a glycoprotein at position 333 containing a natural amino acid whose cocon differs from that of arginine by at least two nucleotides.

Claims (7)

1. Two non-pathogenic mutants isolated from the SAD Berne strain of Canine Poisoning Viruses Collection Nationale de Cultures de Micro-organismes (CNCM) - INSTITUTPASTEUR-France, July 9. 1992 under code I-1238, the mutant has position 333 of glutamic acid. Which its cocon differs from all the codons of Arginine with at least two nucleotides 2. Methods of exposure to two basic mutations according to claim 1, consisting of steps of a) exposure of the rabies virus SAD strain with the first monoclonal antibody that made the SAD strain as It is neutral but does not neutralize the TAG1 strain of the rabies virus, which TAG1 strains were transported under nn-I-433 in the Collection Nationale de Cultures de Micro-organismes. Neutralized by the first monoclonal antibody from the SAD strain of the rabies virus; c) nucleotide sequencing of the amino acid position 333 of the glycoprotein of the SAD mutant. The isolation of the SAD mutation with lysine in position 333 from the SAD mutant with a nucleotide sequence in the ce step) monocloid preparation. A second nal antibody neutralized both the SAD strain and the SAD mutant that was isolated in the b step but did not neutralize the TAG1 strain and f) its non-neutralized isolation of the mutant. By Mo Mo Second clonal antibody from the aforementioned SAD mutant selected in stage b. 3. Isolated non-pathogenic rabies vaccine containing the underlying mutant. Two non-pathogenic sequences of SAD strains of the rabies virus. Glycoproteins, which exist in position 333, are naturally formed amino acids, which their codons differ from arginine's total codons by Two or more nucleodides Where the two basic, non-pathogenic mutations were obtained from A process consisting of steps of a) exposure of the rabies virus SAD strain with the first monoclonal antibody, which neutralized the SAD strain but did not neutralize the TAG1 strain of the rabies virus to which the TAG1 strain was transmitted. It was stored under n ° -I-433 in the Collection Nationale de Cultures de Micro-organismes. B) Selection of its mutants unbased by one such monoclonal antibody from the SAD strain of the disease virus. C) nucleotide sequencing of the amino acid position 333 of the glycoprotein of the said SAD mutant selected in the bd stage) isolation of its SAD mutant which had Lysine was positioned 333 from the aforementioned SAD mutants with a nucleotide sequence in the ce step) second monoclonal antibody preparation, which neutralized both the SAD strains and the aforementioned SAD mutants. And f) isolation of the mutant, which was not neutralized by the second monoclonal antibody, from the SAD mutant at Was selected in step b. 4. Vaccine according to claim 3, where amino acid in position 333 is glutamic acid. 5. Isolated non-pathogenic rabies vaccine containing the underlying mutant. Two non-pathogenic sequences exist in position 333 where amino acids are formed, in which their codons differ from the codon. Total of arginine by at least two nucleodides This includes steps of a) exposure of the rabies virus SAD strain with the first monoclonal antibody, which neutralized the SAD strain but did not neutralize the TAG1 strain of the rabies virus to which the TAG1 strain was transported. B) Selection of its mutants that were not neutralized by the first monoclonal antibody from the SAD strain of the rabies virus was identified under n ํ-I-433 in the Collection Nationale de Cultures de Micro-organismes. C) Nucleotide sequencing of the amino acid position 333 of the glycoprotein of the aforementioned SAD mutants selected in the bd step). Scene 333 from the aforementioned SAD mutants with a nucleotide sequence in the ce step) second monoclonal antibody preparation, which neutralized both the SAD strains and the aforementioned SAD mutants at It was isolated in a step b but did not neutralize the TAG1 strain and f) its mutant isolation, which was not neutralized by the second monoclonal antibody, from the aforementioned SAD mutant. T A in step b 6. Vaccine according to claim 3, where the mutant is a mutant of the SAD Berne strain. 7. Vaccine according to claim 6, where a mutant is a mutant transported in the Collection Nationale de Cultures de Micro-organismes C.N.C.M-Institut. PASTEUR-France, on July 9, 1992, under I-1238, a mutant with a 333 position of glutamic acid, its cocon is different from all codons. Of arginine at least two nucleotides